{"hands_on_practices": [{"introduction": "Effective delirium prevention begins with a clear assessment of a patient's unique risk profile and a pragmatic plan to mitigate those risks, especially in urgent surgical settings where time and resources are limited. This first exercise [@problem_id:5174002] challenges you to step into the role of a clinical strategist. You will use evidence-based estimates of an intervention's impact ($RR$) and its real-world feasibility ($f$) to prioritize and sequence a series of preventive actions for a high-risk patient, honing your ability to make high-impact decisions under pressure.", "problem": "A $78$-year-old man scheduled for urgent fixation of a hip fracture is classified as American Society of Anesthesiologists (ASA) Physical Status class $IV$ for severe systemic disease (heart failure with reduced ejection fraction and chronic kidney disease). He takes multiple medications including oxybutynin and diphenhydramine, has moderate hearing loss without his hearing aids, and has impaired vision from cataracts. He is cognitively intact at baseline. The team’s aim is to minimize postoperative delirium, defined as an acute, fluctuating disturbance in attention and cognition after surgery, by selecting and sequencing a set of feasible perioperative interventions.\n\nUse the following fundamental bases to guide your reasoning:\n- Postoperative delirium risk increases with anticholinergic burden (consistent with the cholinergic deficiency hypothesis), sensory deprivation, deep anesthesia, sleep disruption, uncontrolled pain, hypoxia, and immobility. Multicomponent nonpharmacologic bundles mitigate several of these drivers simultaneously.\n- Relative risk (RR) is the ratio of event probability under an intervention to the event probability without the intervention. Expected value reasoning dictates prioritizing actions that maximize expected absolute risk reduction, adjusted by feasibility (probability that the action can be successfully implemented in the given setting).\n\nAssume the baseline probability of postoperative delirium in this patient population without targeted mitigation is $p_0 = 0.45$. From high-quality studies applicable to this context, you may take the following well-tested approximate effects and feasibility estimates for single interventions applied independently in this setting:\n- Medication reconciliation and targeted deprescribing to remove anticholinergics and avoid perioperative benzodiazepines: $RR = 0.60$; feasibility $f = 0.90$.\n- Sensory enhancement and orientation measures (portable hearing amplifiers at bedside, ensuring eyeglasses or temporary visual aids, orientation board, family call schedule): $RR = 0.70$; $f = 0.95$.\n- Multicomponent nonpharmacologic delirium-prevention bundle (sleep hygiene, early mobilization, reorientation, hydration, constipation prevention, daytime light exposure): $RR = 0.75$; $f = 0.70$ given staffing constraints.\n- Intraoperative depth-of-anesthesia monitoring to avoid unnecessarily deep anesthesia while maintaining adequate hypnosis and analgesia: $RR = 0.85$; $f = 1.00$.\n- Regional analgesia (fascia iliaca block) with multimodal opioid-sparing analgesia: $RR = 0.80$; $f = 0.85$.\n\nAssume independence of effects for the purpose of ranking single-action expected impacts, and that feasibility $f$ reflects the probability of full, protocol-concordant implementation for each intervention. Your goal is to prioritize the sequence of interventions for this patient by ordering them from first to last to maximize expected reduction in delirium cases per $100$ similar patients, while also considering time-to-implement in the urgent preoperative window and the plausibility of reliably delivering the intervention in this institution.\n\nWhich sequence most appropriately prioritizes risk mitigation actions based on expected impact and feasibility in this setting?\n\nA. Deprescribe anticholinergics and avoid benzodiazepines → Sensory enhancement and orientation → Multicomponent bundle → Regional analgesia with multimodal regimen → Depth-of-anesthesia monitoring\n\nB. Depth-of-anesthesia monitoring → Regional analgesia with multimodal regimen → Multicomponent bundle → Sensory enhancement and orientation → Deprescribe anticholinergics and avoid benzodiazepines\n\nC. Sensory enhancement and orientation → Multicomponent bundle → Depth-of-anesthesia monitoring → Regional analgesia with multimodal regimen → Deprescribe anticholinergics and avoid benzodiazepines\n\nD. Multicomponent bundle → Sensory enhancement and orientation → Deprescribe anticholinergics and avoid benzodiazepines → Depth-of-anesthesia monitoring → Regional analgesia with multimodal regimen", "solution": "Begin from the provided core definitions and principles. Postoperative delirium arises via interacting pathways that include reduced central cholinergic transmission, impaired sensory input reducing orientation and attention, sleep-wake disruption, inflammatory and metabolic stress, and iatrogenic contributors such as deep anesthesia and high-dose opioids. A rational prioritization should therefore:\n- Prefer actions that directly counter the strongest pathophysiologic drivers that are present and modifiable in this patient.\n- Weight benefits by both the magnitude of risk reduction and the probability that the intervention can be successfully and reliably implemented in this urgent care pathway.\n\nFrom probability theory, if the baseline risk without an intervention is $p_0$, and a single intervention has relative risk $RR$, then the absolute risk with that intervention alone is $p_0 \\times RR$, and the absolute risk reduction is $p_0 \\times (1 - RR)$. If there is uncertainty or variability in implementation, we incorporate feasibility $f$ as the probability that the intervention is successfully delivered, producing an expected absolute risk reduction of $p_0 \\times (1 - RR) \\times f$. Expressing this per $100$ patients multiplies by $100$.\n\nCompute the expected absolute risk reduction per $100$ patients for each intervention using $p_0 = 0.45$:\n\n- Deprescribe anticholinergics and avoid benzodiazepines:\n  Absolute risk reduction per patient is $0.45 \\times (1 - 0.60) = 0.45 \\times 0.40 = 0.18$.\n  Adjust for feasibility $0.90$: $0.18 \\times 0.90 = 0.162$.\n  Per $100$ patients: $0.162 \\times 100 = 16.2$ prevented cases.\n\n- Sensory enhancement and orientation:\n  Absolute risk reduction per patient is $0.45 \\times (1 - 0.70) = 0.45 \\times 0.30 = 0.135$.\n  Adjust for feasibility $0.95$: $0.135 \\times 0.95 = 0.12825$.\n  Per $100$ patients: $0.12825 \\times 100 = 12.825$ prevented cases.\n\n- Multicomponent bundle:\n  Absolute risk reduction per patient is $0.45 \\times (1 - 0.75) = 0.45 \\times 0.25 = 0.1125$.\n  Adjust for feasibility $0.70$: $0.1125 \\times 0.70 = 0.07875$.\n  Per $100$ patients: $0.07875 \\times 100 = 7.875$ prevented cases.\n\n- Depth-of-anesthesia monitoring:\n  Absolute risk reduction per patient is $0.45 \\times (1 - 0.85) = 0.45 \\times 0.15 = 0.0675$.\n  Adjust for feasibility $1.00$: $0.0675 \\times 1.00 = 0.0675$.\n  Per $100$ patients: $0.0675 \\times 100 = 6.75$ prevented cases.\n\n- Regional analgesia with multimodal regimen:\n  Absolute risk reduction per patient is $0.45 \\times (1 - 0.80) = 0.45 \\times 0.20 = 0.09$.\n  Adjust for feasibility $0.85$: $0.09 \\times 0.85 = 0.0765$.\n  Per $100$ patients: $0.0765 \\times 100 = 7.65$ prevented cases.\n\nRank by expected prevented cases per $100$ patients:\n- Deprescribing anticholinergics and avoiding benzodiazepines: $16.2$ (highest).\n- Sensory enhancement and orientation: $12.825$.\n- Multicomponent bundle: $7.875$.\n- Regional analgesia with multimodal regimen: $7.65$.\n- Depth-of-anesthesia monitoring: $6.75$.\n\nThis ordering also aligns with mechanistic salience in this patient: anticholinergic burden directly worsens central cholinergic transmission, a core driver of delirium, and is highly feasible to reverse immediately with pharmacist-led reconciliation. Sensory enhancement rapidly restores environmental cues and attention, which is both impactful and easy to implement at bedside before and after surgery. The multicomponent bundle addresses multiple smaller contributors and should be initiated early and continued postoperatively, but feasibility constraints reduce its expected average impact. Regional analgesia and multimodal regimens meaningfully reduce opioid exposure and pain-related delirium drivers, but in aggregate yield slightly less expected prevention than the bundle in the given estimates. Depth-of-anesthesia monitoring contributes additional risk reduction but is relatively smaller in expected average impact than the preceding measures.\n\nTime-to-implement considerations in an urgent case are consistent with this ranking: deprescribing and ordering non-benzodiazepine alternatives can occur immediately; sensory aids can be instituted preoperatively and continued postoperatively; bundle elements can be activated early postoperatively despite staffing variability; regional blocks can be placed perioperatively; depth monitoring, while simple to turn on intraoperatively, yields the smallest expected incremental prevention under these estimates and thus appears later in priority.\n\nOption-by-option analysis:\n- Option A lists: Deprescribing → Sensory enhancement → Multicomponent bundle → Regional analgesia → Depth monitoring. This matches the computed rank by expected impact and is consistent with urgent feasibility. Verdict — Correct.\n\n- Option B lists: Depth monitoring → Regional analgesia → Multicomponent bundle → Sensory enhancement → Deprescribing. This inverts the data-driven priorities, placing the smallest expected impact first and the largest last, and thus does not maximize expected reduction. Verdict — Incorrect.\n\n- Option C lists: Sensory enhancement → Multicomicomponent bundle → Depth monitoring → Regional analgesia → Deprescribing. This front-loads moderate-impact measures and delays the highest-impact deprescribing to last, which is suboptimal by both expected value and pathophysiology. Verdict — Incorrect.\n\n- Option D lists: Multicomponent bundle → Sensory enhancement → Deprescribing → Depth monitoring → Regional analgesia. This delays the highest-impact deprescribing until third and misorders the tail measures relative to expected impacts. Verdict — Incorrect.", "answer": "$$\\boxed{A}$$", "id": "5174002"}, {"introduction": "As highlighted in the previous exercise, medication management is a cornerstone of delirium prevention, and polypharmacy with anticholinergic agents is a potent risk factor. This practice [@problem_id:5173972] moves from broad strategy to tactical execution. It equips you with a quantitative method—the Anticholinergic Cognitive Burden (ACB) scale—to systematically assess a patient's medication list and make evidence-based deprescribing decisions that reduce delirium risk while preserving therapeutic intent.", "problem": "A patient on a systemic surgery service is on postoperative day $1$ after open abdominal surgery. Prevention and management of postoperative delirium is a priority. A well-tested clinical observation is that pharmacological antimuscarinic effects impair central cholinergic transmission, which worsens attention and increases the likelihood of delirium. The Anticholinergic Cognitive Burden (ACB) instrument classifies individual medications into ordinal categories $1$, $2$, or $3$ that reflect increasing anticholinergic cognitive burden; tools based on expert consensus and pharmacologic profiling apply these categories to estimate regimen burden. The patient’s current inpatient medication list (indication in parentheses) with ACB categories is:\n\n- Diphenhydramine $25$ mg nightly (insomnia): ACB $3$.\n- Oxybutynin extended-release $10$ mg daily (overactive bladder): ACB $3$.\n- Amitriptyline $25$ mg nightly (neuropathic pain): ACB $3$.\n- Cyclobenzaprine $5$ mg three times daily as needed (muscle spasm): ACB $2$.\n- Paroxetine $20$ mg daily (major depressive disorder): ACB $3$.\n- Promethazine $25$ mg as needed (nausea): ACB $3$.\n- Chlorpheniramine $4$ mg twice daily (allergic rhinitis): ACB $3$.\n\nTo preserve therapeutic intent for each indication while minimizing delirium risk, the team considers substitutions. The following substitution options are available, with their ACB categories and clinical constraints derived from the patient’s current status: blood pressure $182/112$ mmHg, corrected QT interval $470$ ms, estimated glomerular filtration rate $35$ mL/min/1.73 m$^{2}$, alanine aminotransferase $5 \\times$ upper limit of normal, history of seizure disorder, and prior postoperative delirium precipitated by gabapentin.\n\n- Insomnia: melatonin (ACB $0$) is permitted; trazodone (ACB $1$) is permitted.\n- Overactive bladder: mirabegron (ACB $0$) is contraindicated because of severe uncontrolled hypertension; no other non-anticholinergic alternatives are available; one antimuscarinic must be continued.\n- Neuropathic pain: duloxetine (ACB $0$) is contraindicated due to hepatic enzyme elevation; gabapentin (ACB $0$) is contraindicated due to prior delirium; pregabalin (ACB $0$) is unavailable; nortriptyline (ACB $3$) is the only tolerated effective option.\n- Muscle spasm: baclofen (ACB $0$) is permitted; tizanidine (ACB $0$) is contraindicated due to hypotension risk in this patient.\n- Major depressive disorder: sertraline (ACB $0$) is permitted; escitalopram (ACB $0$) is contraindicated due to prolonged $QT$; bupropion (ACB $0$) is contraindicated due to seizure disorder.\n- Nausea: ondansetron (ACB $0$) is contraindicated due to prolonged $QT$; metoclopramide (ACB $0$) is permitted.\n- Allergic rhinitis: cetirizine (ACB $0$) and loratadine (ACB $0$) are permitted.\n\nAssume that for each indication, exactly one agent must be selected to preserve therapeutic intent, selected from the current agent or one of the permitted substitutions for that indication. Under these constraints, and using the widely accepted practice that the regimen’s anticholinergic cognitive burden is assessed by aggregating the categorical contributions of the active agents, determine the minimal attainable total burden for this patient’s regimen. Express your final answer as an integer without units. No rounding is required.", "solution": "The problem requires the minimization of the total Anticholinergic Cognitive Burden ($B_{total}$), which is defined as the sum of the ACB scores ($B_i$) for the selected medication for each of the $n=7$ indications.\n$$B_{total} = \\sum_{i=1}^{7} B_i$$\nTo find the minimal total burden, $B_{total, min}$, we must determine the minimal possible ACB score for each indication, $B_{i, min}$, subject to the given constraints, and then sum these values.\n$$B_{total, min} = \\sum_{i=1}^{7} B_{i, min}$$\nWe will now analyze each indication to find the optimal choice, defined as the permitted medication with the lowest ACB score.\n\n1.  **Insomnia**: The current medication is Diphenhydramine (ACB $3$). The permitted substitutions are Melatonin (ACB $0$) and Trazodone (ACB $1$). To minimize the burden, we must choose the option with the lowest ACB score.\n    $$B_{1, min} = \\min(3, 0, 1) = 0$$\n    The optimal choice is Melatonin.\n\n2.  **Overactive bladder**: The current medication is Oxybutynin (ACB $3$). The substitution Mirabegron (ACB $0$) is contraindicated due to severe hypertension. A critical constraint states, \"one antimuscarinic must be continued.\" Oxybutynin is an antimuscarinic. No other antimuscarinic options are provided for this indication. Therefore, the choice is fixed.\n    $$B_{2, min} = 3$$\n    The only possible choice is to continue Oxybutynin.\n\n3.  **Neuropathic pain**: The current medication is Amitriptyline (ACB $3$). The substitutions Duloxetine (ACB $0$), Gabapentin (ACB $0$), and Pregabalin (ACB $0$) are all ruled out due to contraindications or unavailability. The only remaining option for substitution is Nortriptyline (ACB $3$), which is described as the \"only tolerated effective option,\" reinforcing that it is the forced choice if a change is made. The set of available choices is therefore {Amitriptyline, Nortriptyline}.\n    $$B_{3, min} = \\min(3, 3) = 3$$\n    The minimal burden for this indication is $3$.\n\n4.  **Muscle spasm**: The current medication is Cyclobenzaprine (ACB $2$). The substitution Tizanidine (ACB $0$) is contraindicated. The substitution Baclofen (ACB $0$) is permitted. The available choices are Cyclobenzaprine and Baclofen.\n    $$B_{4, min} = \\min(2, 0) = 0$$\n    The optimal choice is Baclofen.\n\n5.  **Major depressive disorder**: The current medication is Paroxetine (ACB $3$). The substitutions Escitalopram (ACB $0$) and Bupropion (ACB $0$) are contraindicated. The substitution Sertraline (ACB $0$) is permitted. The available choices are Paroxetine and Sertraline.\n    $$B_{5, min} = \\min(3, 0) = 0$$\n    The optimal choice is Sertraline.\n\n6.  **Nausea**: The current medication is Promethazine (ACB $3$). The substitution Ondansetron (ACB $0$) is contraindicated. The substitution Metoclopramide (ACB $0$) is permitted. The available choices are Promethazine and Metoclopramide.\n    $$B_{6, min} = \\min(3, 0) = 0$$\n    The optimal choice is Metoclopramide.\n\n7.  **Allergic rhinitis**: The current medication is Chlorpheniramine (ACB $3$). The substitutions Cetirizine (ACB $0$) and Loratadine (ACB $0$) are both permitted. The available choices are Chlorpheniramine, Cetirizine, and Loratadine.\n    $$B_{7, min} = \\min(3, 0, 0) = 0$$\n    The optimal choice is either Cetirizine or Loratadine.\n\nThe minimal total anticholinergic burden is the sum of the minimum scores for each indication.\n$$B_{total, min} = B_{1, min} + B_{2, min} + B_{3, min} + B_{4, min} + B_{5, min} + B_{6, min} + B_{7, min}$$\n$$B_{total, min} = 0 + 3 + 3 + 0 + 0 + 0 + 0$$\n$$B_{total, min} = 6$$\nThe minimal attainable total burden for the patient's regimen is $6$.", "answer": "$$\\boxed{6}$$", "id": "5173972"}, {"introduction": "While prevention is paramount, clinicians must also be adept at managing delirium when it occurs, and a critical step is identifying the underlying cause. This final exercise [@problem_id:5174052] presents a complex case where postoperative delirium is driven by severe alcohol withdrawal. It challenges you to differentiate this specific etiology from general postoperative delirium and apply a distinct, evidence-based protocol, reinforcing the principle that effective treatment is mechanism-based.", "problem": "A $62$-year-old man with a history of hypertension and daily alcohol intake of approximately $8$ standard drinks presents for an elective laparoscopic sigmoid colectomy. On postoperative day $2$, he becomes acutely confused, disoriented to place and time, and intermittently combative. Vital signs show heart rate $122\\,\\mathrm{beats/min}$, blood pressure $164/92\\,\\mathrm{mmHg}$, temperature $37.7\\,^\\circ\\mathrm{C}$, and oxygen saturation $96\\%$ on room air. He reports visual hallucinations of “insects on the wall,” has coarse tremor, diaphoresis, and psychomotor agitation. Nursing notes indicate that his last alcoholic drink was approximately $36$ hours before admission. Laboratory evaluation reveals aspartate aminotransferase (AST) $146\\,\\mathrm{U/L}$, alanine aminotransferase (ALT) $58\\,\\mathrm{U/L}$, total bilirubin $2.4\\,\\mathrm{mg/dL}$, and normal serum creatinine. The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) score is $18$, with a score distribution notable for tremor $6$, agitation $5$, hallucinations $4$, and anxiety $3$. His Richmond Agitation-Sedation Scale (RASS) is $+2$.\n\nYou are asked to design a protocol that aligns with prevention and management principles for postoperative delirium in systemic surgery. The protocol must be justified from first principles of neuropharmacology and validated assessment tools, making explicit why benzodiazepines are generally avoided in postoperative delirium but are indicated for alcohol withdrawal. The protocol should incorporate: (i) parenteral thiamine administration before any glucose-containing solutions, (ii) symptom-triggered benzodiazepine dosing guided by CIWA-Ar thresholds, and (iii) an adjunctive phenobarbital strategy for benzodiazepine-refractory cases, with safety monitoring. Consider hepatic function when selecting agents.\n\nWhich of the following protocols is most appropriate?\n\nA. Initiate haloperidol $2\\,\\mathrm{mg}$ intravenous every $6$ hours for delirium control, avoid benzodiazepines entirely because they worsen delirium, begin $5\\%$ dextrose infusion immediately for nutrition, and reassess CIWA-Ar only once daily. Do not give thiamine because the patient is eating. Avoid phenobarbital due to risk of respiratory depression.\n\nB. Administer intravenous thiamine $100\\,\\mathrm{mg}$ before any glucose-containing fluids; employ a symptom-triggered benzodiazepine regimen guided by CIWA-Ar: for CIWA-Ar $\\geq 8$–$10$, give lorazepam $1$–$2\\,\\mathrm{mg}$ intravenous, repeat every $10$–$15$ minutes until the patient is calm but arousable, and reassess CIWA-Ar hourly; for CIWA-Ar $\\geq 15$ or persistent agitation despite cumulative lorazepam $6$–$8\\,\\mathrm{mg}$, add phenobarbital $130$–$260\\,\\mathrm{mg}$ intravenous as adjunct, with continuous cardiorespiratory monitoring and airway readiness; otherwise avoid benzodiazepines for non–alcohol-withdrawal delirium and prioritize nonpharmacologic measures with antipsychotics only if severe agitation threatens safety.\n\nC. Begin fixed-schedule diazepam $10\\,\\mathrm{mg}$ intravenous every $6$ hours regardless of CIWA-Ar, provide $500\\,\\mathrm{mL}$ of $10\\%$ dextrose before thiamine to correct hypoglycemia faster, and administer phenobarbital $260\\,\\mathrm{mg}$ intravenous upfront to all agitated postoperative patients to prevent progression to delirium tremens. Reassess CIWA-Ar every $8$ hours.\n\nD. Treat postoperative delirium with lorazepam $2\\,\\mathrm{mg}$ intravenous every $4$ hours to ensure sleep restoration in all cases because benzodiazepines are broad-spectrum anxiolytics; CIWA-Ar is not necessary postoperatively. If agitation persists, increase lorazepam to $4\\,\\mathrm{mg}$ intravenous every $2$ hours. Administer thiamine after stabilization and start glucose immediately to prevent catabolism. Avoid phenobarbital due to drug interactions.\n\nE. Start dexmedetomidine infusion at $0.2$–$0.7\\,\\mathrm{\\mu g/kg/h}$ to prevent and treat delirium while avoiding benzodiazepines entirely; do not obtain CIWA-Ar because continuous sedation controls symptoms; phenobarbital is unnecessary; thiamine can be given after glucose since the infusion dose is small. Reassess with the RASS only.", "solution": "The clinical presentation—including a history of heavy alcohol use, the timing of symptoms (postoperative day 2, approximately 84 hours after the last drink), autonomic hyperactivity (tachycardia, hypertension), and specific neurological signs (tremor, agitation, hallucinations)—is a classic manifestation of severe alcohol withdrawal syndrome (AWS), specifically delirium tremens (DTs), not general postoperative delirium. Therefore, the management protocol must be tailored to this specific etiology.\n\nThe correct protocol is based on the following principles:\n1.  **Neuropharmacology of AWS**: AWS is caused by central nervous system hyperexcitability from downregulation of GABA-A receptors. Benzodiazepines (BZDs) are the first-line treatment because they are GABA-A receptor positive allosteric modulators, directly treating the underlying pathophysiology. While BZDs are generally avoided in non-AWS delirium, they are essential and life-saving in AWS.\n2.  **Thiamine Prophylaxis**: Patients with chronic alcoholism are at high risk for thiamine deficiency. Administering glucose before thiamine can precipitate Wernicke's encephalopathy. The correct sequence is always thiamine first.\n3.  **Dosing Strategy and Agent Choice**: Symptom-triggered therapy using a validated scale (CIWA-Ar) is the standard of care. Because of evidence of liver dysfunction (elevated AST, ALT, bilirubin), a BZD that bypasses oxidative hepatic metabolism, like lorazepam, is preferred.\n4.  **Refractory AWS**: For patients who do not respond to high doses of BZDs, adjunctive therapy with an agent like phenobarbital is a standard escalation strategy, which requires intensive cardiorespiratory monitoring.\n\nAnalyzing the options:\n*   **Option A** is incorrect. It fails to treat AWS by avoiding BZDs and dangerously administers glucose before thiamine.\n*   **Option B** correctly incorporates all the key principles: thiamine before glucose, symptom-triggered lorazepam (appropriate for liver impairment), hourly CIWA-Ar monitoring, and a clear escalation plan to phenobarbital with appropriate safety precautions. It also correctly notes the specific indication for BZDs in this context.\n*   **Option C** is incorrect. It uses a suboptimal fixed-schedule regimen, a less ideal agent (diazepam), and reverses the thiamine/glucose order.\n*   **Option D** is incorrect. It inappropriately generalizes BZD use to all delirium, dismisses the essential CIWA-Ar scale, and reverses the thiamine/glucose order.\n*   **Option E** is incorrect. Dexmedetomidine is an adjunct, not a primary treatment for AWS, as it does not prevent seizures. Avoiding BZDs is dangerous.\n\nTherefore, option B represents the current evidence-based standard of care for severe postoperative alcohol withdrawal.", "answer": "$$\\boxed{B}$$", "id": "5174052"}]}